Voy Review 2026: Is It Worth It for GLP-1 Medication in the UK?

Voy is currently the largest online GLP-1 prescribing service in the UK by patient volume, with the company reporting over 1.5 million patients at the time of writing. When a service is that large, the honest review question is not just "does it work?" but "does it work for the kind of person I am, with the kind of support I need?"

This review answers that question honestly, covering everything from the onboarding process to what happens when you have a problem between consultations.

What Is Voy?

Voy is a UK-registered online weight management clinic that prescribes GLP-1 medications (primarily Wegovy and Mounjaro) following an online medical consultation. It operates within the regulatory framework for online prescribing in the UK and partners with registered pharmacies for medication supply.

It is not a lifestyle programme in the structured sense. Voy's core offering is:

1. Medical assessment to confirm eligibility
2. Prescription from a registered prescriber
3. Medication delivered to your door
4. Ongoing nurse check-ins and messaging support

It does not lead with behavioural coaching, community, or a comprehensive nutritional programme. Those features exist in lighter forms within the platform, but they are not the main event.

Who Can Use Voy?

Eligibility for Voy's GLP-1 programme follows standard NHS-adjacent criteria:

• BMI of 30 or above
• BMI of 27 or above if you have a weight-related health condition (such as type 2 diabetes, hypertension, or PCOS)
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, etc.)
• Not currently pregnant or breastfeeding
• Not already prescribed insulin or certain other diabetes medications

The eligibility questionnaire covers these systematically. If you fall outside the criteria, the system will tell you at the questionnaire stage before you provide payment details, which is appropriate.

Medications Available

Voy prescribes both of the main GLP-1 medications currently available in the UK:

Wegovy (semaglutide): Once-weekly injection. The STEP 1 trial showed average weight loss of 14.9% of body weight over 68 weeks. This is currently the NHS-approved medication for obesity treatment.

Mounjaro (tirzepatide): Once-weekly injection. A dual GIP/GLP-1 agonist with stronger clinical trial data in terms of average weight loss (SURMOUNT-1 trial: up to 22.5% at the highest dose). Mounjaro was licensed in the UK for type 2 diabetes management and, more recently, for chronic weight management.

Both medications are available on the standard Voy platform, and the prescriber will recommend one based on your clinical profile. In practice, the initial recommendation often starts with Wegovy, with Mounjaro as an alternative if Wegovy is unavailable due to supply constraints or if you have a clinical preference.

Pricing

Voy's pricing is structured per month and increases with dose as expected. As of 2026:

| Medication | Starting dose | Therapeutic dose (monthly est.) | |-----------|--------------|--------------------------------| | Wegovy | £149/month | £169-£199/month | | Mounjaro | £149/month | £179-£219/month |

These prices include the medication, nurse consultations, and access to the patient platform. They do not include private blood tests if you want those separately, though Voy does include some screening as part of onboarding.

The price at therapeutic dose is competitive compared to most independent private clinics charging £200-£300+ for the same medication. The trade-off is the support model, which is lighter than premium services.

The Onboarding Process

The Voy onboarding is well-designed and largely digital. Here is what the process looks like in practice:

Step 1: Online questionnaire. You complete a detailed medical questionnaire covering weight history, relevant medical conditions, current medications, contraindications, and lifestyle factors. This takes approximately 15-20 minutes and is thorough.

Step 2: Nurse consultation. A video or phone consultation with a nurse prescriber follows. The consultation typically runs 15-30 minutes and covers the questionnaire findings, your expectations, and your commitment to the programme. The nurse will ask about your weight history, previous weight loss attempts, and any conditions relevant to prescribing. This is a genuine clinical assessment, not a rubber stamp.

Step 3: Prescription and delivery. If appropriate, a prescription is issued and the medication is dispatched via the partner pharmacy. Delivery typically arrives within 2-5 working days.

Step 4: Ongoing check-ins. Nurse consultations are scheduled at intervals (typically monthly or at dose escalation points). Between these, the Voy platform allows messaging to clinical staff.

What's Included

A Voy subscription includes:

• Nurse-led consultations at onboarding and key dose escalation points
• Messaging access to clinical staff between consultations
• Access to the Voy patient app with tracking and information content
• Medication supply (the core of the service)
• Dose adjustment guidance

What's Not Included

This is the honest part. Voy does not include:

• Dietitian-led nutritional coaching
• Women-specific hormonal health guidance
• Structured lifestyle behaviour change programme
• Community or peer support network
• On-demand GP access

If you have questions about nutrition on GLP-1s, Voy will point you to their in-app content. The content is decent but not personalised. If you have PCOS or are perimenopausal and want your treatment to address those dimensions, Voy's team is competent but not specifically trained in that context.

Support Quality: The Honest Assessment

The support model works well for people who are comfortable managing their own side effects with good information, and who are not needing frequent clinical contact. For early weeks, particularly during dose escalation where GI side effects can be significant, 48-hour message response times are a real limitation.

Voy's Trustpilot score as of early 2026 is 4.3 out of 5, with positive reviews predominantly praising the medication supply reliability and initial consultation quality. Negative reviews tend to cluster around response times and the feeling that the service becomes less attentive once the prescription is in place.

This is not unusual for high-volume online prescribers, but it is worth knowing going in.

Supply Reliability

One of Voy's genuine strengths is supply chain reliability. During the Wegovy shortage of 2023-2024, Voy navigated supply constraints better than many competitors, partly due to its scale and pharmaceutical partnerships. The medication supply is one of the more dependable aspects of the service.

Who Voy Suits

Voy is a good fit for:

• Women who are self-sufficient, comfortable with digital services, and do not anticipate needing intensive clinical support
• Those who have done their research and understand the medication, the dose escalation, and common side effects
• Women for whom price is a significant consideration
• Those who are not managing complex hormonal health contexts alongside weight loss

Voy is a less good fit for:

• Women with PCOS who want integrated hormonal support (consider Lola Health instead)
• Perimenopausal women who want their weight context understood in full
• Anyone who tends to need frequent clinical reassurance during treatment changes
• Women who want a structured lifestyle programme as the framework for their treatment

For a comparison of all major UK GLP-1 clinics, see the best GLP-1 clinics in the UK 2026 guide.

How Voy Compares to the NHS Route

The NHS route for GLP-1 at obesity doses involves referral to a specialist weight management service. This gives access to multidisciplinary support, including dietitians and psychologists, but requires meeting strict eligibility criteria and waiting. The full criteria are detailed in NHS Wegovy eligibility UK 2026.

If you qualify for the NHS pathway and can wait, it is the more comprehensive clinical experience. Voy is the right choice if you meet private eligibility criteria and want to start without waiting.

Voy and Side Effects

For managing the early weeks of treatment, whether via Voy or any other clinic, the same principles apply. The side effects of Wegovy in the first 4-8 weeks are significant for many women. The full guide to managing these is in Wegovy side effects in women UK.

If you are considering blood tests before starting (sensible and sometimes not included in basic onboarding), Medichecks offers private testing relevant to baseline assessment.

Protein and Nutrition During Treatment

One practical gap in Voy's offering is nutritional guidance. On a GLP-1, hitting adequate protein becomes important and becomes harder because appetite is suppressed. The risk is muscle loss alongside fat loss, which affects body composition and long-term metabolic rate.

For the full protein strategy on GLP-1 treatment, see protein on GLP-1: complete guide. For the diet strategy overall, see clean eating on GLP-1 in the UK.